Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PBI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPitney Bowes adds La Vonda Williams to Board, assigns to Strategic Review Committee
Filed July 27, 2026 · Period ending July 21, 2026 · ~1 min read
Key Changes
-
medium
La Vonda Williams appointed to Board effective July 21, 2026, with assignment to Strategic Review Committee alongside Audit and Governance committees.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
Williams brings nearly 20 years of finance and operations leadership, including prior CFO role at Onegevity Health and VP position at Goldman Sachs.
Exhibit 99.1 view on EDGAR → -
low
Compensation includes $200,000 annual cash retainer, $32,000 in committee retainers, and equity grants totaling $306,541 (prorated for mid-year start).
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
Summary
Pitney Bowes appointed La Vonda Williams to its Board of Directors effective July 21, 2026, with immediate assignment to the Strategic Review Committee established in connection with the company's previously announced strategic review process. Williams will also serve on the Audit and Governance committees. Her background includes CFO experience at Onegevity Health through its 2021 acquisition and nearly six years at Goldman Sachs in equity derivatives operations, plus prior board service at Altra Industrial Motion Corporation.
The Strategic Review Committee assignment is the notable element. Williams receives an additional $278,000 equity grant (prorated to $225,446 for her mid-year start) specifically for that committee service, on top of standard director compensation. The filing characterizes her capital markets experience and transaction background as relevant to the committee's work, suggesting the board is adding financial expertise as it evaluates strategic alternatives.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On July 21, 2026, Pitney Bowes Inc. (the “Company”) appointed La Vonda Williams to its Board of Directors (“the Board”). Ms. Williams has been named to the Audit Committee, the Governance Committee and the Strategic Review Committee
The company appointed La Vonda Williams to its Board of Directors effective July 21, 2026. She will serve on three committees: Audit, Governance, and Strategic Review. Ms. Williams brings nearly 20 years of finance and operations leadership experience, including prior CFO roles and investment banking positions at Goldman Sachs.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
an annual cash retainer of $200,000;
•an additional annual cash retainer of $20,000 for service on the Audit Committee and $12,000 for service on the Governance Committee;
•an annual equity grant in the form of restricted stock units, the number of which will be calculated by dividing $100,000 ($81,095 as prorated to reflect Ms. Williams’ mid-year start date) by the fair market value of a share of the Company’s common stock, $1 par value (a “Share”), as of the award date, which will fully vest one year later; and
•for service on the Strategic Review Committee that was formed in connection with the Company’s previously announced strategic review process, an additional equity grant in the form of restricted stock units, the number of which will be calculated by dividing $278,000 ($225,446 as prorated to reflect Ms. Williams’ mid-year start date) by the fair market value of a Share as of the award date, which will fully vest one year later.
Ms. Williams will receive standard non-management director compensation including a $200,000 annual cash retainer, additional retainers for committee service totaling $32,000, and equity grants. The equity includes a standard $100,000 annual grant (prorated to $81,095 for mid-year start) and an additional $278,000 grant (prorated to $225,446) for Strategic Review Committee service, both vesting in one year.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Pitney Bowes Inc. (NYSE: PBI) (“Pitney Bowes” or the “Company”), a technology-driven company that provides digital shipping solutions, mailing innovation, and financial services to clients around the world, today announced the appointment of La Vonda Williams to its Board of Directors (the “Board”), effective immediately.
Pitney Bowes added La Vonda Williams to its Board of Directors effective immediately. Williams brings financial and operational leadership experience from senior executive and director roles at public and private companies, including service as a director of Altra Industrial Motion Corporation prior to its 2023 merger with Regal Rexnord. She will serve on the Board's Strategic Review Committee.
Added in current filing · view on EDGAR →
Given her additive perspectives, she will serve as a member of the Board’s recently established Strategic Review Committee.
Williams will serve on the Board's recently established Strategic Review Committee. The filing notes her background includes deep involvement in corporate assessments of strategic alternatives and transaction opportunities, as well as capital markets insight from her time at investment banks including Goldman Sachs.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Ms. Williams is the former Chief Financial Officer of Onegevity Health, a health intelligence company with a precision health and wellness platform, where she served from 2019 until its acquisition by Thorne HealthTech, Inc. in 2021. Prior to joining Onegevity, she served as Vice President of Equity Derivatives Operations at Goldman Sachs from 2014 to 2019.
Williams served as CFO of Onegevity Health from 2019 until its 2021 acquisition by Thorne HealthTech, and as Vice President of Equity Derivatives Operations at Goldman Sachs from 2014 to 2019. She has nearly 20 years of leadership experience across finance and operations, and previously served as an Independent Director of Altra Industrial Motion Corporation from 2021 to 2023, where she was a member of the Audit Committee.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 28, 2026 · How we verify